Study guide

9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias

Key Takeaways Explain This Topic AI

Bernard-Soulier syndrome results from defective GP Ib/IX/V complexes causing giant platelets, mild thrombocytopenia, and absent ristocetin agglutination that fails to correct with normal plasma, whereas Glanzmann thrombasthenia involves deficient GP IIb/IIIa integrins with normal platelet morphology and absent aggregation to physiological agonists despite normal ristocetin response.

Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) present as X-linked recessive disorders with deep joint hemarthroses and isolated prolonged aPTT, whereas von Willebrand Disease (vWD) causes mucocutaneous hemorrhage with abnormal platelet function closure times, reduced vWF:Ag, and defective RIPA that corrects with normal plasma.

Severe liver failure is definitively differentiated from isolated Vitamin K deficiency by measuring Factor V activity: Factor V is synthesized in the liver independent of Vitamin K, rendering it decreased in hepatic necrosis but entirely normal in pure Vitamin K deficiency.

Acute Disseminated Intravascular Coagulation (DIC) represents an uncontrolled consumptive coagulopathy characterized by microvascular thrombosis, secondary hyperfibrinolysis, thrombocytopenia, prolonged PT/aPTT, hypofibrinogenemia, elevated D-dimer, and microangiopathic schistocytes.

Factor V Leiden (Arg506Gln mutation conferring Activated Protein C resistance) is the most prevalent hereditary thrombophilia, while Antiphospholipid Syndrome produces in vitro phospholipid-dependent test prolongation (aPTT, dRVVT) despite triggering severe in vivo arterial and venous thrombosis.

Last updated: October 2026

Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias

Hemostatic disorders fall into two major clinical categories: hemorrhagic diatheses (bleeding disorders caused by quantitative or qualitative platelet defects, coagulation factor deficiencies, or accelerated fibrinolysis) and hypercoagulable states (thrombophilias predisposing to inappropriate microvascular, venous, or arterial thrombosis). Accurate diagnosis requires correlating clinical bleeding manifestations with quantitative automated coagulometry, platelet aggregometry, mixing algorithms, and molecular testing.

  • 1. Quantitative and Qualitative Platelet Disorders
  • Thrombocytopenia: Etiological Mechanisms

Thrombocytopenia is defined as a peripheral blood platelet count of < 150 × 10 9 / L <150 \times 10^9/\text{L} < 150 × 1 0 9 / L . Significant clinical purpura, petechiae, and mucosal oozing typically manifest when counts drop below 50 × 10 9 / L 50 \times 10^9/\text{L} 50 × 1 0 9 / L , with high risk for spontaneous intracranial or internal hemorrhage at counts < 10 to 20 × 10 9 / L <10\text{ to }20 \times 10^9/\text{L} < 10 to 20 × 1 0 9 / L .

Impaired Bone Marrow Production : Characterized by decreased megakaryocytes on bone marrow examination. Etiologies include aplastic anemia, acute leukemias, marrow infiltration (myelophthisis), cytotoxic chemotherapy, and megaloblastic anemia (ineffective thrombopoiesis accompanied by hypersegmented neutrophils).

Immune Thrombocytopenic Purpura (ITP) : Acquired autoimmune disorder driven by pathogenic IgG autoantibodies directed against platelet membrane glycoproteins, primarily GP IIb/IIIa or GP Ib/IX . Opsonized platelets are sequestered and phagocytosed by splenic reticuloendothelial macrophages via Fc γ \gamma γ receptors. Bone marrow examination reveals normal to increased megakaryocytes (compensatory megakaryocytic hyperplasia). Peripheral smear shows marked thrombocytopenia with occasional stress megathrombocytes. PT, aPTT, and fibrinogen are completely normal.

Thrombotic Microangiopathies (TMA) :

Thrombotic Thrombocytopenic Purpura (TTP) : Caused by severe deficiency ( < 10 % <10\% < 10% enzymatic activity ) of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for cleaving ultra-large von Willebrand factor (UL-vWF) multimers secreted by endothelial Weibel-Palade bodies into smaller, less adhesive plasma multimers. Severe deficiency (most often acquired via inhibitory IgG autoantibodies) allows uncleaved UL-vWF multimers to anchor to the endothelium, spontaneously tethering passing platelets into widespread, occlusive microvascular platelet thrombi throughout the microcirculation. Clinical presentation features the classic Pentad :

Microangiopathic Hemolytic Anemia (MAHA) with marked schistocytes ( > 1 % >1\% > 1% on peripheral smear), polychromasia, and nucleated red blood cells

  • Severe Thrombocytopenia (frequently < 20 × 10 9 / L <20 \times 10^9/\text{L} < 20 × 1 0 9 / L )
  • Fluctuating Neurological Signs (headache, confusion, transient ischemic attacks, seizures, coma)
  • Renal Impairment (hematuria, proteinuria, mild azotemia)
  • Fever

Crucial Coagulation Profile : In TTP, thrombi are composed purely of platelets and vWF without systemic activation of the coagulation cascade. Therefore, PT, aPTT, and Fibrinogen are completely NORMAL ! This is the definitive discriminator separating TTP from DIC. Emergency therapy is Therapeutic Plasma Exchange (TPE) with Fresh Frozen Plasma (FFP), which removes autoantibodies and supplies active ADAMTS13; platelet transfusions are strictly contraindicated as they precipitate new microvascular thrombosis.

Hemolytic Uremic Syndrome (HUS) : Typical HUS occurs predominantly in pediatric patients following gastroenteritis caused by Shiga toxin-producing Escherichia coli (STEC, serotype O157:H7) or Shigella dysenteriae . Shiga toxin binds to globotriaosylceramide (Gb3) receptors on renal glomerular capillary endothelium, triggering endothelial cytotoxicity, localized platelet-fibrin microthrombi, and acute cortical necrosis. Presents with the pediatric Triad : MAHA with schistocytes, thrombocytopenia, and severe Acute Renal Failure / oliguria . ADAMTS13 activity is normal ( > 10 % >10\% > 10% ); PT, aPTT, and fibrinogen are normal.

Heparin-Induced Thrombocytopenia (HIT Type II) : An immune-mediated adverse drug reaction developing 5 to 10 days following exposure to unfractionated heparin (or within 24 hours upon heparin re-exposure). Pathogenic IgG antibodies form against macromolecular complexes of Platelet Factor 4 (PF4) and Heparin . The Fc regions of these IgG antibodies engage Fc γ \gamma γ RIIa receptors on platelets, triggering intense platelet activation, prothrombotic microparticle release, and secondary thrombin generation. Paradoxically, this causes a catastrophic prothrombotic state (venous thromboembolism, limb gangrene, stroke; "white clot syndrome") accompanied by a relative platelet count drop > 50 % >50\% > 50% from baseline. Laboratory diagnosis employs the 4Ts clinical scoring system , PF4/heparin enzyme immunoassays, and the confirmatory gold-standard functional 14 C ^{14}\text{C} 14 C -Serotonin Release Assay (SRA) . Management requires immediate cessation of all heparin and initiation of alternative non-heparin anticoagulation with direct thrombin inhibitors ( argatroban, bivalirudin ) or fondaparinux.

  • Qualitative Platelet Disorders: Bernard-Soulier vs. Glanzmann ┌──────────────────────────────────────────────┐
  • │ Qualitative Platelet Defect Workup │
  • └──────────────────────┬───────────────────────┘
  • │
  • ┌───────────────────────────────┴───────────────────────────────┐
  • ▼ ▼
  • ┌──────────────────────────────┐ ┌──────────────────────────────┐
  • │ Bernard-Soulier Syndrome │ │ Glanzmann Thrombasthenia │
  • └──────────────┬───────────────┘ └──────────────┬───────────────┘
  • │ │
  • Defect: GP Ib/IX/V complex • Defect: GP IIb/IIIa complex
  • Impairment: Platelet Adhesion to vWF • Impairment: Platelet Aggregation (fibrinogen)
  • Blood Smear: Giant Platelets (4-8 µm) • Blood Smear: Normal morphology, isolated platelets
  • Platelet Count: Mildly DECREASED • Platelet Count: NORMAL
  • Aggregometry: • Aggregometry:
  • ADP, Collagen, Epinephrine: NORMAL - ADP, Collagen, Epinephrine: ABSENT / FLAT
  • Ristocetin: ABSENT (No correction with normal plasma) - Ristocetin: NORMAL agglutination
  • Flow Cytometry: Absent CD42b (GP Ib), CD42a (GP IX) • Flow Cytometry: Absent CD41 (GP IIb), CD61 (GP IIIa)

Bernard-Soulier Syndrome (BSS) :

Inheritance and Defect : Autosomal recessive deficiency or molecular dysfunction of the Glycoprotein GP Ib/IX/V receptor complex .

Pathophysiology : Platelets cannot bind subendothelial von Willebrand factor under high shear rates, completely blocking initial primary hemostatic adhesion.

Diagnostic Smear & Morphology : Peripheral blood smear demonstrates hallmark Giant Platelets (diameter 4 to 8 μ \mu μ m, frequently approaching the size of erythrocytes) and mild-to-moderate thrombocytopenia ( 20 to 100 × 10 9 / L 20\text{ to }100 \times 10^9/\text{L} 20 to 100 × 1 0 9 / L ).

Platelet Aggregometry : Completely absent agglutination with Ristocetin , which FAILS TO CORRECT upon addition of normal pooled plasma (because the platelet membrane itself lacks the functional receptor). Aggregation in response to physiological agonists ( ADP, Collagen, Epinephrine, Arachidonic acid ) is completely NORMAL .

Glanzmann Thrombasthenia (GT) :

Inheritance and Defect : Autosomal recessive deficiency or structural mutation of the Glycoprotein GP IIb/IIIa integrin complex ( α IIb β 3 \alpha_{\text{IIb}}\beta_3 α IIb ​ β 3 ​ ) .

Pathophysiology : Platelets adhere normally to subendothelial collagen and vWF, but activated platelets cannot bind plasma fibrinogen to form inter-platelet cross-links, completely abolishing platelet aggregation.

Diagnostic Smear & Morphology : Peripheral blood smear shows a completely normal platelet count and normal morphology ; however, platelets on stained smears remain scattered individually as single elements without forming the normal aggregated clusters.

Platelet Aggregometry : Severely flat, completely absent aggregation with all physiological agonists (ADP, Collagen, Epinephrine, Thrombin) . Agglutination in response to Ristocetin is entirely NORMAL (since GP Ib and vWF are intact).

  • 2. Congenital Coagulation Factor Deficiencies
  • Hemophilia A, B, and C
  • Feature Hemophilia A Hemophilia B Hemophilia C
  • Factor Deficiency Factor VIII:C (Antihemophilic A) Factor IX (Christmas Factor) Factor XI (PTA)
  • Inheritance Pattern X-linked Recessive X-linked Recessive Autosomal Recessive

Prevalence 1 in 5,000 live male births (~85% of cases) 1 in 30,000 live male births (~15% of cases) Rare (highest in Ashkenazi Jewish heritage)

Clinical Hallmarks Deep joint hemarthroses, soft-tissue hematomas Indistinguishable from Hemophilia A Mild mucosal oozing, post-operative bleeding

PT / aPTT Profile Normal PT / Prolonged aPTT Normal PT / Prolonged aPTT Normal PT / Prolonged aPTT

Definitive Diagnosis Specific Factor VIII coagulant assay Specific Factor IX coagulant assay Specific Factor XI coagulant assay

Therapeutic Management Recombinant FVIII; Emicizumab (bispecific) Recombinant FIX concentrates Factor XI concentrates; FFP

Clinical Severity Classification for Hemophilia A and B :

Severe ( < 1 % <1\% < 1% factor activity, < 0.01 IU/mL <0.01\text{ IU/mL} < 0.01 IU/mL ) : Frequent spontaneous, unprovoked bleeding into large hinge joints ( hemarthroses in knees, elbows, ankles), leading to chronic, debilitating hemophilic arthropathy; deep intramuscular hematomas; retroperitoneal hemorrhages; and life-threatening intracranial bleeding.

Moderate (1% to 5% factor activity) : Rare spontaneous bleeds; severe hemorrhage following mild blunt trauma or minor surgical procedures.

Mild (5% to 40% factor activity) : Asymptomatic in daily life; prolonged, severe hemorrhage discovered only after major surgical interventions, tooth extractions, or severe trauma.

Emicizumab Mechanism : A recombinant, humanized bispecific monoclonal antibody that binds simultaneously to Factor IXa and Factor X, mimicking the cofactor function of activated Factor VIIIa. Because its molecular structure differs from Factor VIII, it is effective in Hemophilia A patients who have developed inhibitory alloantibodies against Factor VIII.

von Willebrand Disease (vWD)

von Willebrand Disease is the most prevalent inherited human bleeding disorder , affecting approximately 1% of the population. Inherited in autosomal dominant or recessive patterns, it results from quantitative reductions or qualitative structural defects in von Willebrand factor (vWF) .

Dual Physiological Roles of vWF :

Platelet Adhesion : vWF acts as a molecular bridge tethering platelet membrane GP Ib/IX/V to subendothelial collagen under high vascular shear rates.

Factor VIII Carrier : vWF forms a non-covalent circulating complex with Factor VIII, stabilizing its quaternary structure and extending its intravascular plasma half-life from ~2 hours to 10–12 hours. Without vWF, Factor VIII is rapidly cleared from the circulation.

Clinical Manifestations : In contrast to hemophilia (which manifests with deep joint and muscle bleeds), vWD characteristically presents with mucocutaneous bleeding : recurrent epistaxis, menorrhagia, gingival bleeding, easy cutaneous ecchymoses, and prolonged bleeding from small lacerations.

Classification of vWD :

Type 1 (~75% to 80% of cases) : Autosomal dominant partial quantitative deficiency of structurally normal vWF multimers. Responsive to Desmopressin (DDAVP) , which induces exocytosis of endogenous vWF and Factor VIII stored in endothelial Weibel-Palade bodies.

Type 2 (~15% to 20%) : Qualitative defects in vWF structure or function:

Type 2A : Decreased platelet-dependent function accompanied by loss of high-molecular-weight (HMW) multimers due to abnormal multimer assembly or increased cleavage by ADAMTS13.

Type 2B : Gain-of-function mutation in the vWF A1 domain causing hyper-affinity for platelet GP Ib; vWF binds spontaneously to circulating platelets, leading to rapid clearance of both HMW multimers and platelets, causing mild, episodic thrombocytopenia and enhanced Ristocetin-Induced Platelet Agglutination (RIPA) at low ristocetin concentrations ( 0.5 mg/mL 0.5\text{ mg/mL} 0.5 mg/mL ).

Type 2M : Decreased platelet-dependent function with normal multimer distribution.

Type 2N (Normandy) : Autosomal mutation impairing vWF binding to Factor VIII; circulating Factor VIII is rapidly cleared, mimicking mild hemophilia A but exhibiting autosomal rather than X-linked inheritance.

Type 3 (<1%) : Severe autosomal recessive total quantitative absence of vWF. vWF antigen is undetectable, and secondary Factor VIII activity is profoundly depressed ( < 5 % <5\% < 5% ), producing severe mucosal hemorrhage and hemarthroses.

Diagnostic Laboratory Profile for vWD :

Platelet Count : Normal (except mild thrombocytopenia in Type 2B).

PT : Completely normal.

aPTT : Normal or mildly prolonged (depending on the degree of secondary Factor VIII reduction).

Bleeding Time / PFA-100 : Markedly prolonged closure times with Collagen/Epinephrine and Collagen/ADP cartridges.

vWF Antigen (vWF:Ag) : Quantitative immunoassay (ELISA or latex turbidimetry) measuring total vWF protein concentration (decreased in Types 1 and 3; normal in Type 2).

vWF Ristocetin Cofactor Activity (vWF:RCo) : Functional assay measuring agglutination of formalin-fixed donor platelets in the presence of ristocetin and patient plasma (ratio of vWF:RCo / vWF:Ag < 0.7 \text{vWF:RCo} / \text{vWF:Ag} < 0.7 vWF:RCo / vWF:Ag < 0.7 indicates a qualitative Type 2 defect).

RIPA Aggregometry : Defective at standard ristocetin concentrations; CRITICAL DISTINCTION : Defective RIPA in vWD CORRECTS completely upon adding normal pooled plasma or cryoprecipitate (which supplies exogenous vWF), whereas Bernard-Soulier syndrome fails to correct!

  • 3. Acquired Bleeding Disorders: Liver Disease, Vitamin K Deficiency, and DIC
  • Severe Hepatic Disease vs. Isolated Vitamin K Deficiency

Because the liver parenchyma synthesizes nearly all procoagulant factors and natural anticoagulant inhibitors, distinguishing primary hepatocellular failure from isolated nutritional or biliary Vitamin K deficiency is a frequent clinical challenge: Prolonged PT/INR and aPTT

  • │
  • Measure Factor V Activity
  • │
  • ┌──────────────────┴──────────────────┐
  • ▼ ▼
  • **Factor V is NORMAL** **Factor V is DECREASED**
  • │ │
  • ▼ ▼
  • **Pure Vitamin K Deficiency** **Severe Liver Disease**
  • Obstructive Jaundice / Cholestasis • Cirrhosis / Acute Hepatic Necrosis
  • Malabsorption / Antibiotic therapy • Impaired synthesis of all factors
  • Rapid correction with IV Vitamin K • Unresponsive to parenteral Vitamin K

Vitamin K Deficiency : Factors II, VII, IX, and X, along with Proteins C and S, are undercarboxylated. Because Factor VII has the shortest half-life (~6 hours), PT prolongs first , followed by aPTT. Factor V is synthesized in hepatocytes independent of Vitamin K ; therefore, in pure Vitamin K deficiency, Factor V activity is completely NORMAL .

Severe Liver Disease (Cirrhosis / Fulminant Hepatic Failure) : Global suppression of hepatocyte protein synthesis depresses Factors I, II, V, VII, IX, X, XI, Antithrombin, and Protein C. Factor V activity is markedly DECREASED . (Factor VIII is synthesized predominantly in sinusoidal endothelial cells and remains normal or elevated as an acute-phase reactant).

Disseminated Intravascular Coagulation (DIC)

DIC is an acquired, life-threatening clinicopathological syndrome characterized by systemic, unregulated activation of coagulation, leading to diffuse microvascular fibrin deposition, multi-organ failure, and a severe consumption coagulopathy with secondary hyperfibrinolysis:

Triggering Etiologies : Sepsis/severe infection (endotoxin/cytokine release), obstetric catastrophes (amniotic fluid embolism, abruptio placentae releasing placental tissue factor), Acute Promyelocytic Leukemia (APL / AML-M3: neoplastic promyelocytes contain tissue factor-rich granules that trigger massive clotting; treated emergently with all-trans retinoic acid [ATRA]), massive crush trauma, and envenomation.

Pathophysiological Vicious Cycle :

Massive intravascular exposure of Tissue Factor drives systemic, uncontrolled thrombin generation.

Microvascular thrombi occlude organ capillary beds, causing multi-organ dysfunction (renal failure, respiratory distress, hepatic failure).

Extensive clotting exhausts and consumes circulating platelets, fibrinogen, Factor V, Factor VIII, and Prothrombin.

Widespread microvascular thrombi stimulate endothelial tPA release, driving massive secondary fibrinolysis. Plasmin cleaves fibrin into massive quantities of FDPs and D-dimers , which coat platelets and inhibit fibrin polymerization, precipitating catastrophic systemic bleeding (oozing from surgical wounds, puncture sites, hematuria, gastrointestinal hemorrhage).

Acute Overt DIC Diagnostic Profile :

Platelet Count : Severe, rapidly progressive thrombocytopenia ( < 50 × 10 9 / L <50 \times 10^9/\text{L} < 50 × 1 0 9 / L ) .

PT and aPTT : Markedly prolonged due to consumptive factor depletion.

Fibrinogen : Profound hypofibrinogenemia ( < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL ) .

D-Dimer and FDPs : Markedly elevated (diagnostic hallmark of concurrent thrombin and plasmin activity).

Peripheral Blood Smear : Microangiopathic Hemolytic Anemia (MAHA) with abundant Schistocytes (helmet cells, triangular RBC fragments) formed by physical shearing of red cells across intravascular fibrin webs.

4. Hereditary and Acquired Thrombophilias (Hypercoagulable States)

Thrombophilia refers to an inherited or acquired predisposition to inappropriate venous thromboembolism (VTE) or arterial thrombosis.

Factor V Leiden (Activated Protein C Resistance - APCR)

Molecular Genetics : A single point mutation in the F5 gene: guanine to adenine substitution at nucleotide 1691 ( 1691 G > A 1691G>A 1691 G > A ), causing an arginine-to-glutamine amino acid substitution at position 506 ( A r g 506 G l n Arg506Gln A r g 506 Gl n ) .

Biochemical Mechanism : Residue 506 is the primary cleavage site targeted by Activated Protein C (APC) to inactivate Factor Va. The mutated Factor Va protein is resistant to APC-mediated proteolytic inactivation, remaining active in the prothrombinase complex and driving sustained, unregulated thrombin generation.

Epidemiology and Risk : The most common inherited thrombophilia in Caucasian populations (~3% to 8% carrier frequency). Heterozygotes have a 3- to 8-fold increased risk of VTE; homozygotes have up to an 80-fold increased risk.

Laboratory Diagnosis : Clot-based APCR screening test : aPTT is measured in the presence and absence of exogenous APC; an APCR ratio ( a P T T + A P C / a P T T − A P C aPTT_{+APC} / aPTT_{-APC} a PT T + A PC ​ / a PT T − A PC ​ ) < 2.0 <2.0 < 2.0 indicates resistance. Confirmed definitively via PCR DNA molecular testing.

Prothrombin G20210A Mutation

A single point mutation in the 3'-untranslated region of the prothrombin ( F2 ) gene ( 20210 G > A 20210G>A 20210 G > A ) that increases mRNA stability and processing, leading to a 30% elevation in circulating plasma prothrombin (Factor II) levels and a 2- to 3-fold increased lifetime risk of VTE.

Hereditary Deficiencies of Antithrombin, Protein C, and Protein S

Autosomal dominant loss-of-function mutations in SERPINC1 (Antithrombin), PROC (Protein C), or PROS1 (Protein S). Patients present with unprovoked, recurrent venous thromboembolism at a young age (<40 years).

Warfarin-Induced Skin Necrosis : When Warfarin is initiated in a patient with an underlying Protein C or Protein S deficiency without concurrent heparin bridging, the short biological half-life of Protein C (~6 hours) causes its plasma concentration to drop precipitously before procoagulant factors II and X (half-lives 40–72 hours) decline. This induces a temporary, severe hypercoagulable state with widespread microvascular thrombosis of capillary beds supplying skin and subcutaneous adipose tissue, causing catastrophic ischemic cutaneous infarction (breasts, buttocks, thighs).

Antiphospholipid Syndrome (APS) and Lupus Anticoagulant (LA)

Antiphospholipid Syndrome is an acquired autoimmune thrombophilia characterized by persistent circulating autoantibodies directed against phospholipid-binding plasma proteins, primarily β 2 \beta_2 β 2 ​ -glycoprotein I ( β 2 GPI \beta_2\text{GPI} β 2 ​ GPI ) and Prothrombin .

Clinical Features : Recurrent venous thrombosis (DVT, PE), arterial thrombosis (ischemic stroke, transient ischemic attacks), and obstetric complications (unexplained recurrent first-trimester miscarriages, fetal death after 10 weeks gestation, severe preeclampsia).

The In Vitro / In Vivo Diagnostic Paradox :

In Vitro : Lupus anticoagulants bind to reagent phospholipids used in clotting assays, sterically interfering with tenase and prothrombinase assembly and paradoxically PROLONGING phospholipid-dependent clotting tests (aPTT, dilute Russell Viper Venom Time dRVVT) .

In Vivo : These autoantibodies activate platelets, endothelial cells, and monocytes, potently driving THROMBOSIS in vivo!

ISTH Standardized 3-Step Laboratory Diagnostic Algorithm :

Screening Step : Demonstration of a prolonged phospholipid-dependent clotting test (dRVVT screen or LA-sensitive aPTT with low phospholipid content). dRVVT directly activates Factor X via Daboia russelii venom, bypassing upstream factors.

Mixing Step : Failure of the prolonged screening test to correct when mixed 1:1 with Pooled Normal Plasma (confirms the presence of a circulating inhibitor rather than a factor deficiency).

Confirmatory Step : Significant shortening or normalization of the clotting time upon adding an excess of confirmatory bilayer phospholipids (e.g., dRVVT Confirm reagent or frozen-thawed platelet membranes in the Platelet Neutralization Procedure). The excess phospholipids absorb the lupus anticoagulant autoantibodies, neutralizing the inhibition and proving phospholipid dependence.

5. Diagnostic Differential Table: Bleeding and Thrombotic Disorders

Condition Platelet Count PT / INR aPTT Fibrinogen D-Dimer Key Laboratory Hallmark Clinical Phenotype

Bernard-Soulier Syndrome Mild ↓ \downarrow ↓ ( 20 – 100 20\text{--}100 20 – 100 ) Normal Normal Normal Normal Giant platelets; absent ristocetin aggregation; fails to correct with normal plasma Severe mucosal bleeding, epistaxis

Glanzmann Thrombasthenia Normal Normal Normal Normal Normal Normal count/morphology; absent aggregation to ADP/collagen/epi; normal ristocetin Mucosal hemorrhage, purpura

Hemophilia A Normal Normal Prolonged Normal Normal Low Factor VIII:C; normal vWF:Ag; corrects on 1:1 mix Deep joint hemarthroses, hematomas

von Willebrand Disease (Type 1) Normal Normal Normal / ↑ \uparrow ↑ Normal Normal Low vWF:Ag; low vWF:RCo; RIPA abnormal, corrects with normal plasma Mucocutaneous bleeding, menorrhagia

Acute Overt DIC Severe ↓ \downarrow ↓ ( < 50 <50 < 50 ) Prolonged Prolonged Marked ↓ \downarrow ↓ ( < 100 <100 < 100 ) Markedly ↑ ↑ \uparrow\uparrow ↑↑ Schistocytes on smear; consumptive coagulopathy with hyperfibrinolysis Diffuse bleeding + microvascular thrombosis

Thrombotic Thrombocytopenic Purpura (TTP) Severe ↓ \downarrow ↓ ( < 20 <20 < 20 ) Normal Normal Normal Normal / Mild ↑ \uparrow ↑ Severe ADAMTS13 deficiency ( < 10 % <10\% < 10% ); abundant schistocytes on smear Pentad: MAHA, thrombocytopenia, neuro signs, fever, renal

Factor V Leiden (APCR) Normal Normal Normal Normal Normal APCR ratio < 2.0 <2.0 < 2.0 ; positive PCR DNA for Arg506Gln mutation Venous thromboembolism (DVT, PE)

Antiphospholipid Syndrome (Lupus Anticoagulant) Normal / Mild ↓ \downarrow ↓ Normal / ↑ \uparrow ↑ Prolonged Normal Normal Fails to correct on 1:1 mix; shortens with excess confirmatory phospholipids Paradoxical thrombosis, recurrent pregnancy loss